Institute an expedited review track for applications focused on drug discovery, preclinical, and clinical drug development for Alzheimer’s disease to mitigate erosion of patent life and to allow a viable commercialization strategy for NIH supported molecules.
Ensure that review panels for translational research applications are staffed with adequate cross-disciplinary expertise to evaluate all aspects of drug discovery and development for a variety of therapeutic targets and therapeutic modalities.
Encourage industry utilization of NIH funding to increase the number of therapeutic agents and therapeutic mechanisms tested in phase II proof of mechanism trials.
- Establish an NIH working group to develop an expedited review track for translational AD and ADRD research applications (from target identification/validation drug discovery through Phase III clinical trials).
- Research Implementation Area
- Translational Tools, Infrastructure and Capabilities
- To Be Initiated